International Asthma Conference at Nemacolin
0

CME Overview

The World’s Leading Asthma Experts

Conference Overview

Despite significant advances in our understanding of the pathophysiology and treatment of asthma, and the availability of national and international guidelines on the diagnosis and treatment of asthma, recent surveys show that asthma control and morbidity have not improved. Research is being conducted to address many of these issues. This conference will bring the latest research developments in this rapidly changing field to health care professionals practicing, researching, and teaching asthma care.

Asthma exists in diverse environments and populations and varies in severity by time and patient. Moreover, based on the results of recent research, asthma is being viewed less as a disease and more as a syndrome with multiple phenotypes and endotypes. The resultant heterogeneity forms the basis for the education and discussion embedded in the International Asthma Conference at Nemacolin, which takes pride in being one of the only conferences in the world dedicated exclusively to asthma. Its purpose is to create a highly interactive educational environment, including the world’s best asthma researchers, teachers, and clinicians, to critique cutting-edge research and translate key research findings into clinical pearls that will benefit patients with asthma.

 

Target Audience and Learning Objectives

Target Audience:

  • All practicing allergists/immunologists and pulmonologists

  • Fellows in allergy/immunology and pulmonary training programs

  • Primary care physicians who care for asthma patients

  • Allied health professionals with interest in asthma

Following this conference, participants should be able to:

  • Describe the range of asthma cohorts and their different foci.

  • Discuss the insights these cohorts have produced.

  • Identify the future research questions the cohorts will examine.

  • Discuss clinical and molecular phenotyping in relation to asthma

  • Discuss differences in pediatric compared to adult phenotypes

  • Compare the application and limitations of old and new biomarkers

  • Discuss the environmental and genetic determinants of asthma.

  • Discuss the role of social determinants in asthma.

  • Discuss and utilize the safety of asthma therapies.

  • Identify children and adults with side effects of oral and inhaled corticosteroids.

  • Identify the short-term and long-term safety profile of biologic therapies in asthma.

  • Identify new molecular and immunologic research findings about the relationship between viruses and asthma.

  • Identify the role of maternal vaccination in preventing viral infections in infants.

  • Gain a better understanding of the way AI is currently being used to assist clinicians manage their patients.

  • Gain a better understanding of the way AI is currently being used to enhance the clinician-patient experience.

  • Gain a better understanding of the legal and policy challenges facing the expanding use of AI in medicine.

 

Intended Outcome

To positively impact the morbidity and cost of asthma by providing health care practitioners with recommendations on the care of patients with asthma that are based on the most up-to-date research conducted by the world’s leading asthma experts.

 

Accreditation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the WVU School of Medicine and Maci’s Teams. The WVU School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The WVU Office of CME designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physicians
West Virginia University Office of Continuing Education will confirm participation in this educational activity.

Disclosure
It is the policy of the WVU School of Medicine Office of CME to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors/planners participating in our programs are expected to disclose any relevant relationships they may have with commercial companies.

For this conference, Drs Busse, Gern, Kolls, Liu, Lugogo, O’Byrne, Oppenheimer, Panettieri, Petrov, and Wenzel will disclose the relevant relationships with commercial companies. All others have indicated they have no relevant interests to disclose.

The relationships, along with the educational content of this program, will be reviewed and any potential conflicts of interest will be resolved to the satisfaction of the WVU School of Medicine Office of CME.

William W. Busse, MD
Sanofi – Honorarium, Speaker, relationship not terminated, not relevant.
GlaxoSmithKline – Honorarium, Speaker, relationship not terminated, not relevant
Regeneron – Honorarium, Speaker, relationship not terminated
Areteia Therapeutics – Consulting Fees, Data Safety Monitoring Board, relationship not terminated
Elsevier – Royalties, relationship not terminated

James E. Gern, MD
Meissa Vaccines Inc. – Stock options, consulting fees, Consultant, relationship not terminated
Gilead – Consulting fees, Consultant, relationship not terminated
Arrowhead Pharmaceuticals – Consulting fees, consultant, not relevant to presentation, relationship terminated
Merck Inc. – Grant to University of Wisconsin to fund work in my laboratory, ongoing, relevant to presentation, relationship active

Jay K. Kolls, MD
MDRLogix – Equity, intellectual property, Founder

Andrew H. Liu, MD
ResMed – Research grant paid to Children's Hospital Colorado (clinical research site); non-monetary research support for monitoring equipment and data for ancillary research to NIH study, PI, Relationship terminated
AstraZeneca – Honorarium paid to University of Colorado (employer), DSMB member for clinical trial
OM Pharma – Research grant paid to Children's Hospital Colorado (clinical research site)
ThermoFisher Scientific – Consultant. Honorarium paid to University of Colorado (employer)
Revenio – Non-monetary research support for monitoring equipment for ancillary research to NIH study

Njira L. Lugogo, MD
AbbVie – Honorarium, Consultant
Amgen – Honorarium, Grants, Ad board, researcher
Consulting fees – AbbVie, Amgen, Apogee, AstraZeneca, Avillion, Foresee, Genentech, GlaxoSmithKline, Niox, Novartis, Regeneron, Sanofi, and Teva
Honoraria – Non-speakers bureau presentations from GlaxoSmithKline, Teva, Sanofi|Regeneron and AstraZeneca
Travel support – AstraZeneca, Sanofi, Teva, Regeneron, and GlaxoSmithKline
Institution received research support from Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GlaxoSmithKline, Janssen, Regeneron, Roche, Sanofi, Novartis and Teva.
Observational and Pragmatic Research Institute (OPRI) – Honorary faculty member, no compensation

Paul M. O'Byrne, MB, FRCP(C), FRSC
AstraZeneca – Honorarium; Grant-in aid, Speaker and PI
GlaxoSmithKline – Honorarium; Grant-in-aid, Speaker; PI
Advisory Board – Affibody; Sage; Teva;
Honoraria – Sanofi|Regeneron
Grant-in aid – Biohaven; Jasper; Merck

John Oppenheimer, MD
AstraZeneca, GlaxoSmithKline, Aquestive, Aimmune, ARS, Sanofi, Regneron, Novartis – Honorarium, consultant/DSMB/Adjudication Committee

Reynold A. Panettieri, Jr., MD
AstraZeneca – Honorarium, Consultant/Speaker/Research Grant
Sanofi – Honorarium, Speaker
RIFM – Consultant/Advisory Board: Research Grant
Genentech – Advisory Board: Honorarium
Teva – Consultant: Research Grant
GlaxoSmithKline – Research Grant
AgoMab – Research Grant
Medimmune – Research Grant
ACTIV-1 – Research Grant
Janssen – Research Grant
Vault Health – Research Grant
Merck & Co. – Speaker: Honorarium

Andrej Petrov, MD
Eli Lilly – Honorarium, Advisory Board Consultant
Kalvista – Honorarium, Advisory Board Consultant

Sally E. Wenzel, MD
Regeneron – Honorarium, consulting fees. Relationship terminated
Chiese – Honorarium, Consulting fees
Pfizer – Consulting fees
Regeneron – Investigator initiated research study, salary support
Amgen – Multi site PI, salary support

Commercial Support
A special thank you to our sponsors/exhibitors: Genentech, GlaxoSmithKline, and Sanofi Regeneron. More coming soon.

Contact
Please contact Jessica Bolton if you have any questions (jbolton@macisteams.org).